Compare ADMA Biologics Inc (ADMA) vs Brown-Forman Corporation Class B (BF.B) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Brown-Forman Corporation Class B — how do they compare? ADMA Biologics Inc trades at $9.2 (market cap $2.13B), while Brown-Forman Corporation Class B trades at $25.73. The key difference: Brown-Forman Corporation Class B is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | BF.B | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Consumer Staples |
52-Week High | $20.38 | $31.26 |
52-Week Low | $7.60 | $22.80 |
Enterprise Value | $2.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BF.B trades at $25.91, down 0.92% on the day, with a bearish technical outlook per moving averages. Recent earnings show three beats out of four quarters, with Q2 2024 EPS of $0.48 beating the $0.46 estimate. Analyst consensus is mixed, with 25% buy, 50% hold, and 25% sell ratings.
The stock faces near-term pressure from technical weakness, but earnings resilience offers fundamental support. Risks include execution challenges and market sentiment shifts. Upside depends on sustained earnings outperformance and positive analyst revisions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Brown-Forman Corporation Class B
Brown-Forman is the largest U.S.-domiciled producer of distilled spirits. The firm reports only a single operating segment, and whiskey represents its primary business driver, generating roughly three-quarters of sales, undergirded by the Jack Daniel's brand as well as bourbons such as Woodford Reserve and Old Forrester. Notable nonwhiskey offerings include tequilas such as el Jimador and Herradura. The firm operates globally, with products sold in more than 170 countries, and adapts its route-to-consumer model depending on regulation as well as the prevailing competitive dynamics in a given market. For example, it sells through distributors in the U.S. but operates its own logistics apparatus in many other countries. The company remains under the control of the Brown family.
Read more on BF.B →
